Monitor for updates on the Phase III TNBC trial initiation and any interim data readouts, as well as the FDA review of ivonescimab's BLA for EGFR-mutated NSCLC, which could affect the collaboration's trajectory.
Price Chart
Executive Summary
AstraZeneca and Daiichi Sankyo entered a clinical collaboration with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types, starting with a Phase III trial in first-line triple-negative breast cancer. Each company contributes its own medicine and retains commercial rights, with shared trial costs. The collaboration expands the potential addressable market for Datroway, but no financial terms or revenue projections were disclosed.
Key Facts
- AstraZeneca and Daiichi Sankyo entered a clinical collaboration agreement with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types including lung and breast cancers.
- The companies intend to begin with a Phase III trial in 1st-line triple-negative breast cancer (TNBC).
- Each company will contribute their respective medicine for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo.
- AstraZeneca, Daiichi Sankyo, and Summit will each contribute to trial costs, and each company will retain development and commercial rights to their respective medicines.
- AstraZeneca recently announced an equity investment to support clinical collaborations evaluating combinations with ivonescimab, including this agreement for Datroway and a separate agreement for sonesitatug vedotin (Sone-Ve).
- Datroway is approved in more than 30 countries for TNBC and in more than 45 countries for HR-positive, HER2-negative breast cancer, and in the US for EGFR-mutated NSCLC.
- Ivonescimab is approved in China for certain NSCLC patients, and a BLA for EGFR-mutated NSCLC is under FDA review.
Financial Impact
No financial terms disclosed; trial costs shared equally among partners; no upfront or milestone payments mentioned.
Risk Factors
- Clinical trial failure or lack of efficacy in the combination could limit Datroway's label expansion.
- Regulatory delays or negative FDA decisions on ivonescimab could slow the collaboration's progress.
- No financial terms disclosed, making it difficult to assess near-term revenue impact.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008760 |
| Document: 0001654954-26-008760-index-headers.html | 0001654954-26-008760 |
| Document: 0001654954-26-008760-index.html | 0001654954-26-008760 |
| Document: 0001654954-26-008760.txt | 0001654954-26-008760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $171.54 | awaiting T+1 | — | $172.06 (+0.30%) |
Oct 22, 2026 5d ago | 6-K | $172.57 $171.49 | ▼ −0.63% | ▼ −0.10% | $172.06 (−0.30%) |
Oct 15, 2026 12d ago | Court Ruling | $165.41 $163.95 | ▼ −0.88% | ▼ −1.31% | $172.06 (+4.02%) |
Oct 5, 2026 22d ago | 6-K | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $172.06 (+9.92%) |
Oct 2, 2026 25d ago | 6-K | $156.90 $156.53 | ▼ −0.24% | ▼ −0.91% | $172.06 (+9.66%) |
Oct 2, 2026 25d ago | Court Ruling | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $172.06 (+9.92%) |
Oct 1, 2026 25d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $172.06 (+9.11%) |
Oct 1, 2026 25d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $172.06 (+9.11%) |
Sep 29, 2026 28d ago | 6-K | $164.21 $161.47 | ▼ −1.67% | ▼ −1.46% | $172.06 (+4.78%) |
Sep 23, 2026 4w ago | 6-K | $163.33 $164.56 | ▲ +0.75% | ▲ +0.84% | $172.06 (+5.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers